Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of CRPS
3.2.1.2 Advancements in pain management therapies
3.2.1.3 Rising awareness and diagnosis rates
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatment
3.2.2.2 Potential side effects of available therapies
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates & Forecast, By Disease Type, 2021-2032 ($ Mn)
5.1 Key trends
5.2 CRPS I
5.3 CRPS II
5.4 CRPS-NOS
Chapter 6 Market Estimates & Forecast, By Treatment, 2021-2032 ($ Mn)
6.1 Key trends
6.2 Medication
6.2.1 Analgesics
6.2.2 Antidepressants
6.2.3 Corticosteroids
6.2.4 Opioids
6.2.5 Other medications
6.3 Therapy
6.3.1 Physical therapy
6.3.2 Intrathecal drug pump
6.3.3 Spinal cord stimulation
6.3.4 Surgical sympathectomy
6.3.5 Other therapies
Chapter 7 Market Estimates & Forecast, By Route of Administration, 2021-2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Injectable
7.4 Other routes of administration
Chapter 8 Market Estimates & Forecast, By End Use, 2021-2032 ($ Mn)
8.1 Key trends
8.2 Hospitals
8.3 Clinics
8.4 Other end users
Chapter 9 Market Estimates & Forecast, By Region, 2021-2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.6 MEA
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
Chapter 10 Company Profiles
10.1 Abbott Laboratories
10.2 AbbVie
10.3 Averitas Pharma
10.4 Boston Scientific
10.5 Collegium Pharmaceutical
10.6 Eli Lilly and Company
10.7 Mallinckrodt Pharmaceuticals
10.8 Medtronic
10.9 Nevro
10.10 Pfizer
10.11 Sandoz
10.12 Teva Pharmaceutical
